Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
British Journal of Haematology
|
December 3, 1999
CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up-regulated in distinct human leukaemias
A Burchert, M Notter, H Dietrich Menssen, et al.
Endocrine
|
September 18, 2007
Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines
S Hoffmann, A Burchert, A Wunderlich, et al.
Leukemia & Lymphoma
|
March 1, 1997
Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias
A Neubauer, A Burchert, C Maiwald, et al.
Langenbeck'S Archives of Surgery
|
October 21, 2006
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer
S Hoffmann, S Gläser, A Wunderlich, et al.
Molecular and Cellular Biology
|
January 1, 1996
Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase
Y W Fridell, Y Jin, L A Quilliam, et al.
Leukemia
|
September 2, 2005
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert, Y Wang, D Cai, et al.
Leukemia
|
May 24, 2007
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
C Brendel, C Scharenberg, M Dohse, et al.
Leukemia
|
July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G Bug, A Burchert, E-M Wagner, et al.
Leukemia
|
February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
A Burchert, S Saussele, E Eigendorff, et al.
Bone Marrow Transplantation
|
August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
N Kröger, T Zabelina, E Klyuchnikov, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
British Journal of Haematology
|
December 3, 1999
CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up-regulated in distinct human leukaemias
A Burchert, M Notter, H Dietrich Menssen, et al.
Endocrine
|
September 18, 2007
Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines
S Hoffmann, A Burchert, A Wunderlich, et al.
Leukemia & Lymphoma
|
March 1, 1997
Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias
A Neubauer, A Burchert, C Maiwald, et al.
Langenbeck'S Archives of Surgery
|
October 21, 2006
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer
S Hoffmann, S Gläser, A Wunderlich, et al.
Molecular and Cellular Biology
|
January 1, 1996
Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase
Y W Fridell, Y Jin, L A Quilliam, et al.
Leukemia
|
September 2, 2005
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert, Y Wang, D Cai, et al.
Leukemia
|
May 24, 2007
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
C Brendel, C Scharenberg, M Dohse, et al.
Leukemia
|
July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G Bug, A Burchert, E-M Wagner, et al.
Leukemia
|
February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
A Burchert, S Saussele, E Eigendorff, et al.
Bone Marrow Transplantation
|
August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
N Kröger, T Zabelina, E Klyuchnikov, et al.
Page
of 4